Immunosuppressant supplementation to infliximab in Crohn's disease with extraintestinal involvement: a benefit in the long term?
Principi
Mariabeatrice
M
Ierardi
Enzo
E
Antonicelli
Daniela
D
Pastorelli
Alberto
A
Pisani
Antonio
A
Di Leo
Alfredo
A
Panella
Carmine
C
Francavilla
Antonio
A
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy* / Q000473:pathology*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D012074:Remission Induction / Q000379:methods*; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D000069285:Infliximab